| Literature DB >> 9135504 |
M Lemenager1, S Lecomte, M E Bonneterre, E Bessa, J Dauba, J Bonneterre.
Abstract
Docetaxel is a new taxoid antineoplastic agent with clinical efficacy especially in breast cancer. One of the most distressing side-effects induced by docetaxel is alopecia. We studied the prevention of alopecia by using a cold cap in 98 patients receiving 100 mg/m2 docetaxel by 1 h i.v. infusion every 3 weeks. One patient was lost to follow-up. 83 patients (86%) were evaluated as a success to the cold cap, as they presented WHO grade alopecia < or = 2 and no need to wear a wig. 14 patients (14%) had to wear a wig; among them; 7 patients withdrew before the evaluation at three cycles. The cold cap is a very effective technique with minimal side-effects for docetaxel-treated patients.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9135504 DOI： 10.1016/s0959-8049(96)00374-7
Source DB: PubMed Journal: Eur J Cancer ISSN： 0959-8049 Impact factor: 9.162